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Rapport de synthèse 
Utilisation « off-label » de médicaments antidépresseurs 
(OFF-LABEL UTILIZATION OF ANTIDEPRESSANTS) 
De nombreuses études sont effectuées sur les antidépresseurs avant leur mise sur le 
marché, puis des règles précises sont établies pour leur prescription dans des 
indications délimitées. Leur utilisation dans des indications « off-label » (hors 
indication officiellement admise) manque souvent de validation par des bases de 
données scientifiques et leur prescription se base le plus souvent sur un consensus 
proposé par des experts. Le but du présent travail a été d'étudier les ·habitudes de 
prescription de psychiatres d'hôpitaux en ce qui concerne les antidépresseurs, en 
comparant des patients traités pour une dépression et des troubles anxieux avec des 
patients recevant un traitement« off-label ». 
Pour cette étude, les données d'utilisation de médicaments sont celles recueillies lors 
de 6 jours de référence, entre avril 1999 et novembre 2001, à l'hôpital psychiatrique 
de Lausanne (Suisse) comprenant 98 lits. La prescription de médicaments. chez 174 
patients a été prise en compte. 
Tandis que le diagnostic n'influençait pas le choix entre des nouveaux et anciens 
antidépresseurs, les patients présentant un trouble anxieux avaient un risque 4.5 fois 
(p < 0.05) plus élevé et les patients présentant un autre diagnostic 8 fois plus élevé 
de recevoir une comédication antipsychotique, en comparaison avec des patients 
dont le diagnostic primaire était un trouble dépressif. De plus, les patients recevant 
comme comédication un hypnotique non-benzodiazépine avaient moins de risque 
que l'on prescrive un ancien antidépresseur (p < 0.05). Alors que les patients avec 
un trouble anxieux et ceux souffrant d'une dépression majeure recevaient un 
antidépresseur à des doses comparables, les patients répondant à une indication off-
label étaient de préférence traités avec des doses plus faibles. 
Les résultats de cette étude suggèrent que les psychiatres d'hôpitaux développent 
des préférences. en ce qui concerne le choix de la classe d'antidépresseurs, et qu'ils 
les utilisent alors aussi bien dans des indications reconnues que non-reconnues. 
Puis ils semblent adapter la dose et la comédication en tenant compte du diagnostic, 
ce qui confirme l'hypothèse initiale de l'étude, 
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Summary: While antidepressant prescription rules are established for approved indications by large-
scale studies, off-label utilization naturally often lacks the validation by large scientific databases, and 
is at its best based on expert consensus. The aim of the present survey was to study the prescription 
habits of hospital psychiatrists with regard to antidepressants, comparing patients treated for 
depressions and anxiety disorder with patients receiving off-label antidepressant treatment. 
Methods 
Data on drug use for this study were based on 6 reference days from April 1999 to November 2001 in 
the 98-bed psychiatrie hospital of the University of Lausanne, Switzerland. The drug prescriptions of 
17 4 patients were assessed. 
Results 
Whereas the diagnosis did not influence the choice between newer or aider antidepressants, patients 
presenting an anxiety disorder were 4.5 times more likely (p<0.05) and patients with other diagnoses 8 
times more likely (p<0.001) to receive an antipsychotic comedication compared to patients whose 
primary diagnosis was a depressive disorder. Also, patients receiving concomitantly a 
nonbenzodiazepine hypnotic were less likely to be prescribed an eider antidepressant (p<0.05). 
While patients with anxiety disorder and those with major depression received their antidepressants at 
comparable doses, patients with an off-label indication were treated preferentially with lower doses. 
Conclusions 
The results of this survey suggest, that the prescribing hospital psychiatrists developed preferences 
with regard to the choice of the antidepressant class, which they then used for both registered and off-
label indications. They then seemed to adapt the dose and the comedication according to the 
diagnosis, confirming the initial study hypothesis. 
Key words: Antidepressants; Prescription habits; Off-label use; Depression; Anxiety disorders 
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Introduction 
The analysis of factors which influence the prescription of psychotropic drugs, and especially 
antidepressants, has repeatedly been the subject of recent research (2, 4). Prescription habits have 
been shown to be especially influenced by characteristics of the regional health care system, 
physician management style, physician specialty and training, public attitudes, drug cost and 
availability, patient preferences, local tradition, education, marketing and formulary (5, 7, 8, 13, 19) . 
Conversely, prescribing physicians seem to take less into account patient characteristics (5, 8). 
A major source of concern of many drug utilization studies has been the appropriateness of 
psychotropic drug prescribing practices, pointing out the frequent lack of concordance between 
psychiatrie diagnoses and prescribed psychotropic medications (4, 8, 18). 
Wh ile tricyclic antidepressants were rapidly used for other indications after their introduction, this 
broadening of indications has been even more of an issue for the newer generation antidepressants. 
Many of the newer drugs can presently be considered valid alternatives, especially in the treatment of 
anxiety disorders (3) and eating disorders (10). Their popularity for the treatment of depressive 
symptoms in patients with somatic comorbidities is also largely due to their enhanced safety profiles, 
relative to those observed in older drugs (15). The broad range of diagnoses for which 
antidepressants are prescribed has recently been pointed out in some drug utilization surveys, where 
up to 40 % of patients receiving an antidepressant were not diagnosed with depression (14, 16). 
While guidelines for the use of antidepressant medications have been established for approved 
indications by several large-scale studies, the off-label utilization naturally often lacks this validation, 
and is at most based on expert consensus. 
Whereas differences between patients treated with antidepressants for approved indications and 
those with off-label prescriptions have been found with regard to the intended treatment duration (16), 
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showing shorter treatment duration for off-label utilization, data comparing other aspects of 
antidepressant treatment, such as doses, comedications etc., is stiil lacking. 
The aim of the present survey is to study the prescription habits of hospital psychiatrists with regard to 
antidepressants, comparing patients treated for depression and anxiety disorder with patients 
receiving off-label antidepressant trèatment, examining particularly the administered doses and 
comedications. The underlying hypothesis was that physicians would choose the same class of 
antidepressants in off-label indications as they would for approved indications, but that they would 
adjust doses and comedication in response to the clinical situation. 
Methods 
The present study was developed as part of the AMSP project (Arzneimittelsicherheit in der 
Psychiatrie = drug safety in psychiatry), which is a program for continuous assessment of adverse 
drug reactions in psychiatrie inpatients under naturalistic conditions of routine clinical treatment. The 
methodology has been described elsewhere (6, 21, 23, 24). Currently, more than 35 German, Swiss, 
Austrian, Hungarian and Belgian sites are participating. Data on drug use in the participating hospitals 
are based on two reference days per year. Ali drugs given on a reference day are recorded along with 
age, sex, and diagnosis (ICD-10) for ail patients under surveillance. The daily dosage is also recorded. 
Data of the present study were drawn out of 6 reference days from April 1999 to November 2001 in 
the 98-bed psychiatrie hospital of the University of Lausanne, Switzerland. Currently, the mean 
hospitalization duration is 14 days and the nurse/bed ratio is 0.95. 
Definition of drug classes 
Antidepressants were classified into tricyclic drugs (TCA) and drugs of the newer generations (DNG). 
DNGs were defined as the selective serotonin re-uptake inhibitors paroxetine, sertraline, fluoxetine, 
citalopram and fluvoxamine as weil as mirtazapine, reboxetine, nefazodone and moclobemide. The 
class of TCAs included the tricyclic compounds clomipramine, trimipramine, imipramine, amitriptyline 
and dibenzepin. 
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To analyze the effect of prescribing patterns of sedating vs nonsedating antidepressants and 
concomitant antipsychotic medication or benzodiazepines, the antidepressant group was divided into 
sedating (SA) versus nonsedative drugs (NSA). The sedative compounds were: t~imipramine, 
clomipramine, nefazodone, and mirtazapine. 
Benzodiazepines were classified as one group, including sedative and hypnotic drugs, as sedative 
benzodiazepines were often also used as hypnotics, the different indications therefore being difficult to 
assess .. Nonbenzodiazepine hypnotics (NH) formed a further drug class, including zolpidem, zopiclone 
and zaleplon. 
Dose ranges 
ln order to compare the antidepressant prescription with regard to applied doses, three dose ranges 
were defined for each administered drug (Table 1 ). For patients receiving more than one 
antidepressant, the doses were summed up: twice the low dose range giving a middle dose range, a 
low dose and a middle dose or two middle doses giving a high dose. 
Label and off-label indications 
Based on the primary diagnosis, patients were grouped into 3 classes: (1) Depression, (2) Anxiety 
Disorder, and (3) Other Disorders. 
As no patient had a manie or mixed episode as primary diagnosis, ail patients presenting an ICD-10 
diagnosis of affective disorder were depressive. 
Whereas ail used antidepressants are approved in Switzerland for depression, they differ with regard 
to the approval for the different anxiety disorders. Anxiety disorders were nevertheless grouped into 
one class, as knowledge of the diverse approved indications among the prescribing physicians cou Id 
not be assumed. On the other hahd, physicians are locally trained to consider newer antidepressants 
as the first line pharmacotherapy for anxiety disorders. 
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Analyses 
ln descriptive data analyses means and standard deviations were calculated for numerical variables 
while nominal ones frequency categories values and percentages are reported. ln exploratory 
analyses, the differences between groups were tested with chi-square tests (for nominal variables) 
and analyses of variance for numerical ones. 
Predictive models were built with multivariate logistic regression analysis. Binary stepwise logistic 
regression analysis was used to determine factors predicting the prescription of older antidepressants, 
of antipsychotics, of benzodiazepines and nonbenzodiazepine hypnotics. A further model predicting 
the antidepressant dose range, used was analyzed by multinominal stepwise logistic regression . 
Multinominal logistic regression broke the regression up into a series of binary regressions comparing 
each group to a baseline group, which we determined to be the low dose range group. The backward 
Wald method was applied. 
The data were analyzed using the SPSS for Windows program, version 12.0. 
Results 
Characteristics of the sample 
The drug prescriptions of 17 4 patients were assessed. The mean age was 42.6 ± 11.6 (range 20 - 66) 
. 
and the proportion of women 59.2 %. There were no differences between index days with regard to 
age and sex distribution. 
The distribution regarding the primary ICD-10 diagnosis was: Mental and behavioral disorders due to 
psychoactive substance use (F1 O): 10 (5. 7 %); Schizophrenia, schizotypal and delusional disorders 
(F20): 47 (27.0 %); Mood disorders (F30): 81 (46.6 %); Neurotic, stress-related and somatoform 
disorders (F40): 10 (5.7 %); Behavioral syndromes associated with physiological disturbances and 
physical factors (F50): 1 (0.6 %); Disorders of adult personality and behavior (F60): 25 (14.4 %). 
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Number of prescribed drugs per patient and comedications 
The mean number of drugs administered was 4.3 ± 1.7 (range 1 -10). Forty-eight patients received 
nonbenzodiazepine hypnotics (27.6 %), 138 (79.3 %) had benzodiazepines prescribed, 25 (14.0 %) 
received conventional antipsychotics, 61 (35 %) atypical antipsychotics, 22 (12.6 %) anticonvulsants, 
13 (7.5 %) lithium, and 104 (59.8 %) somatic drugs. There was no secular effect with regard to the 
number of prescribed drugs and comedications when comparing the prescriptions of 1999, 2000 and 
2001. 
Type of antidepressants 
Among the investigated patients, 102 (58.6 %) were treated with SSRls, 18 (10.3·%) patients received 
venlafaxine, 22 (12.6 %) received mirtazapine, 29 (16.7 %) had a tricyclic antidepressant (TCAs), and 
16 (9.2 %) received another drug. Thirteen patients (7.5 %)·were treated simultaneously with two 
antidepressants 
Impact of patients characteristics on antidepressant prescription 
The prescription of the different types of antidepressants for patients with depression, anxiety disorder 
and others are shown in Tab. 2. 
The proportion of patients receiving TCA were 16/81 (19.8 %) for depressive patients, 2/10 (20 %) for 
patients presenting an anxiety disorder, and 11/83 (13.3 %) among the patients with ailother disorder 
(Chi-square 1.322; n.s.) . 
Table 3 shows the result of the stepwise logistic regression, with the choice of an older antidepressant 
being the dependent variable and the index year, the diagnostic class, sex, age and the prescription of 
concomitant drugs (benzodiazepines, nonbenzodiazepine hypnotics, anticonvulsants, lithium, somatic 
drugs) as independent parameters. With increasing age the probability of receiving an older 
antidepressant increased (p<0.05). Furthermore, a clear secular trend appeared, as the probability of 
receiving an older antidepressant was significantly lower in 2000 (p<0.05) and in 2001 (p<0.05) 
compared with 1999. Also, patients receiving concomitantly a nonbenzodiazepine hypnotic were less 
9 
likely t6 be prescribed an older antidepressant (p<0.05). The diagnostic class was not retained as a 
predictive parameter. The positive predictive value of the mode! was 85.1 %. 
Prescription of concomitant antipsychotic drugs 
The correspondent result of the stepwise logistic regression analysis is shown in Tab. 4. The following 
parameters were entered: Index year, sex, age, diagnostic class, antidepressant type (older vs. 
newer) and concomitant treatments. Only the diagnostic class was retained, patients with anxiE:;ty 
disorder or other non-depressive disorders presenting significantly higher odds-ratios compared to 
patients with the diagnosis of depression. The positive predictive value of the definitive mode! was 
73.0 %. 
Prescription of concomitant benzodiazepines 
A stepwise logistic regression predicting the prescription of benzodiazepines including the following 
parameters was computed: Sex, index year, age, diagnostic class, antidepressant type (older vs. 
newer and sedative vs. non-sedative), and concomitant treatments. None of the parameters was 
retained. 
Prescription of concomitant nonbenzodiazepine hypnotics 
The following parameters were used to compute the corresponding stepwise logistic regression (Tab. 
5): Sex, index year, age, diagnostic class, antidepressant type (older vs. newer and sedative vs. non-
sedative), and concomitant treatments. Only the parameter comparing oldervs. newer 
antidepressants was retained. Patients receiving an older antidepressant had a lower probability of 
receiving a concomitant nonbenzodiazepine hypnotic (p<0.05). The positive predictive value of the 
retained model was 72.4 %. 
Dose range 
The distribution with regard to the prescribed doses was: Low dose 48 patients (27.6 %), medium 
dose 96 (55.2 %) and high dose 30 (17.2 %). The multinominal stepwise logistic regression analysis 
was computed with the following parameters: Sex, diagnostic class, antidepressant class (newer vs . 
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older), and prescription of antipsychotics, benzodiazepines, nonbenzodiazepine hypnotics, 
anticonvulsants, lithium or somatic drugs (Tab. 6). The group of individuals having received the 
antidepressant medication at a low dose range were defined as the reference group. The parameters 
of the diagnostic class and of the antidepressant class were retained. Whereas patients with anxiety 
disorder did not differ from those with depressive disorder with regard to the applied doses, those with 
other diagnoses received less often medium (p<0.001) and higher (p<0.001) antidepressant doses. 
Furthermore, those receiving an older antidepressant had an odds ratio of 6.66 to receive their 
antidepressant treatment rather at a high than at low dose, compared to the patients having a 
· treatment with newer antidepressants only (p<0.01 ). 
Discussion 
The aim of ~he present study was to investigate if hospital psychiatrists would prescribe 
antidepressants and comedication differently for patients with a registered indication compared to 
those administered antidepressants on an off-label basis. 
Whereas the diagnosis did not seem to influence the choice of a newer or and aider antidepressant, it 
was significantly associated with the prescription of antipsychotic comedication and antidepressant 
dose. Patients presenting an anxiety disorder were 4.5 times more likely and patients with other 
diagnoses 8 times more likely to receive an antipsychotic comedication compared to patients whose 
primary diagnosis was a depressive disorder. While patients with anxiety disorder and those with 
major depression received their antidepressants at comparable doses, patients with an off-label 
indication were treated preferentially with lower doses. 
While antipsychotics, on one hand, high potency as well as low potency, have often been advocated 
as being valid alternatives to benzodiazepines as anxiolytic treatments, and, on the other hand, 
sedative antidepressants have been suggested to reduce the need of concomitant benzodiazepine 
use, our data did not confirm these assumptions. Neither the use of sedative antidepressants, nor the 
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prescription of benzodiazepines had an impact on the prescription of concomitant antipsychotics. 
Antipsychotics were only prescribed in the function of the diagnosis. 
A secular trend was found with regard to the prescription of tricyclic antidepressants, these older drugs 
being less likely to be prescribed in 2000 and 2001 compared to 1999, even when Checking for 
confounding factors like diagnosis or comedication. As the prescription of a nonbenzodiazepine 
hypnotic was associated With a lowered odds of receiving an older antidepressant, one could 
hypothesize that the observed secular trend may be due to the replacement of tricyclics used for their 
sedative or sleep-enhancing properties by nonbenzodiazepine hypnotics. 
As in previous studies investigating prescription habits of psychotropic drugs (1, 9, 11, 12, 17), 
polypharmacy was highly prevalent, the mean number of prescribed drugs being 4 with a range from 1 
to 1 O drugs per patient. Whereas polypharmacy has long been considered a malpractice in earlier 
studies, it has become increasingly apparent nowadays that psychiatrie polypharmacy can have some 
advantages, i.e., to further improve sleep, have a more potent anxiolytic or sedative effect and to 
overcome therapy resistances (17, 20, 22). 
One further intriguing finding was the observation that the risk of receiving a tricyclic antidepressant 
augmented with increasing age. This is at first sight counter-intuitive, as the risk of cardiovascular and 
other side effects may be more important in eider patients and should have discouraged the doctors 
from prescribing these drugs for those patients. On the other hand, eider patients may be often the 
more chronic patients and may have received the antidepressant for longer habituai treatment, which 
the physician could possibly not have had the courage to change anymore. As the present data are 
only collected on a crossover basis, this assumption can, however, not be tested out. 
The results of this study need to be viewed against their methodological limitations. The method of 
index day assessments allows only cross sectional analyses for each patient. The course of the 
prescription, i.e., titration schemes, and the duration of the antidepressant treatment as well as of the 
comedièations cannot be evaluated. That not every patient can be considered as having been already 
stabilized on the medication at the index day, especially data on doses, but also all other data, has to 
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be interpreted with caution. Also, diagnoses were not based on a structured interview, which may 
have diminished their validity. However, as the ICD-10 diagnoses were derived post hoc from the 
medical records, they surely better reflect clinical practice. Furthermore, only the first diagnosis 
(hospitalization indication) was retained. 
The two reference days were always fixed for the period of late spring and late autumn, allowing each 
center to choose a day within ± 7 days. The choice of seasonally fixed reference days may be a 
confounding factor in depressive disorders as well as anxiety disorders. 
With regard to generalizability, one has to consider that the survey was limited to one site only, the 
hospital being University based and organized in specialized wards. The refuse, biases by local 
customs and conditions of practice cannot be excluded. 
ln conclusion, the present results thus suggest that the prescribing hospital psychiatrists developed 
preferences with regard to the choice of antidepressant class, which they then used for both registered 
and off-label indications. They then seemed to adjust the dose and the comedication according to the 
diagnosis, confirming the initial study hypothesis . 
Factors influencing this spreading out of prescription habits from labeled to off-label indications remain 
to be explored. The results furthermore generate various related important questions, which should be 
addressed through further research: Does the rapid spreading out of off-label prescription increase or 
decrease the risk of adverse drug reactions? Does it unduly increase or decrease costs? What is the 
impact of doctors' interaction with pharmaceutical companies? 
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Tab.1: 
Dose ranges (in mg/d) of antidepressants prescribed in this study 
Low Medium High 
Citalopram <40 40-60 >60 
Fluoxetine <40 40 - 60 >60 
Paroxetine <40 40 -60 >60 
Fluvoxamine <100 100-200 >200 
Sertraline <100 100 - 200 >200 
Venlafaxine <150 150-300 >300 
Nefazodone <200 200 - 400 >400 
Reboxetine <4 4-8 >8 
Mirtazapine <30 30 - 60 >60 
Trimipramine <100 100 - 200 >200 
Clomipramine <150 150 - 300 >300 
lmipramine <150 150 - 300 >300 
Amitriptyline · <150 150 - 300 >300 
Dibenzepin <160 160 - 360 >360 
Moclobemide <300 300 - 600 >600 
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Tab. 2: 
Diagnostic class and type of prescribed antidepressant 
Depression Anxiety Disorder Others 
n % n % n % 
SSRI 34 42.0 8 80.0 51 61.4 
venlafaxine 11 13.6 0 0.0 4 4.8 
mirtazapine 12 14.8 0 0.0 8 9.6 
tca 6 7.4 1 10.0 0 12.0 
others 7 8.6 0 0.0 9 10.8 
combination 11 13.6 1 10.0 1.2 
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Tab. 3: 
Stepwise logistic regression model for use of eider antidepressants 
Age 
Index year 
1999 
2000 
2001 
Nonbenzodiazepine hypnotic 
1.05 
0.24 
0.29 
0.25 
95% Confidence 
lntervals 
1.01 - 1.09 
0.08 - 0.72 
0.10 - 0.84 
0.07 - 0.92 
a Odds ration for the probability of receiving an eider antidepressant 
19 
p 
0.015 
0.011 
0.011 
0.022 
0.037 
Tab.4: 
Stepwise logistic regression mode! for use of concomitant antipsychotic drugs 
Diagnostic class 
Depression 
Anxiety 
Other 
1 
4.51 
8.59 
95% Confidence lntervals 
1.13 - 17.94 
4.19 - 17.60 
a Odds ration for the probability of receiving a concomitant antipsychotic drug 
20 
p 
<0,001 
0.033 
<0,001 
Tab. 5: 
Stepwise logistic regression mode! for use of concomitant nonbenzodiazepine hypnotic 
OR 
Prescription of an aider antidepressant 0.26 
95% Confidence 
lntervalsa 
0.07 - 0.89 
p 
0.032 
a Odds ration for the probability of receiving a concomitant nonbenzodiazepine hypnotic 
21 
Tab. 6: 
Logistic regression mode! for choice of antipsychotic dose range 
Medium dosis High dosis 
95% 
Confidence 95% Confidence 
OR ~ lntervals OR ~ lntervals 
Diagnostic class 
Depression 
Anxiety 0.98 0.988 0,10-9,35 2.21 0.514 0,21-23,83 
1') Other 0.21 <0,001 0,09-0,48 0.08 <0,001 0,03-0,27 
1') Prescription of an older antidepressant 1.11 0.865 0,34-3,56 6.66 0.004 1,82-24,29 
